BKM120 as Second-line Therapy for Advanced Endometrial Cancer

This study has been completed.
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier:
First received: January 26, 2011
Last updated: March 30, 2015
Last verified: March 2015
This is a prospective multi-center, open-label, single arm, Phase II study to investigate the safety and efficacy of BKM120 in patients with advanced endometrial carcinoma whose disease progressed on or after a first-line antineoplastic treatment. Patients will receive BKM120 orally at a dose of 100 mg/day. Availability of tumor specimen (either archival tissue or a fixed fresh biopsy) is mandatory for assessment of the PI3K (Phosphatidylinositol 3 Kinase (PI3K) pathway activation status.

Condition Intervention Phase
Advanced Endometrial Cancer
Drug: BKM120
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II, Single-arm Study of Orally Administered BKM120 as Second-line Therapy in Patients With Advanced Endometrial Carcinoma

Further study details as provided by Novartis:

Primary Outcome Measures:
  • Best Overall Response Rate (BORR) According to PI3K Activation Pathway Status [ Time Frame: 24 months ] [ Designated as safety issue: No ]

    BOR was determined based on investigator assessment of overall lesion response using RECIST criteria guidelines.

    BOR = objective responses rate (ORR), disease control rate (DCR) or clinical benefit rate (CBR). ORR = (complete response (CR) or partial response(PR); DCR = (CR or PR or Stable disease (SD); CBR = (CR or PR od SD >= 24 weeks)

Secondary Outcome Measures:
  • Progression Free Survival (PFS) According to PI3K Activation Pathway Status [ Time Frame: 24 months ] [ Designated as safety issue: No ]
    PFS is defined as the time from start of treatment to the date of first documented progression or death due to any cause. If a patient has not had an event, PFS will be censored at the date of last adequate tumor assessment.

  • Overall Survival (OS) According to PI3K Activation Pathway Status [ Time Frame: every 3 months ] [ Designated as safety issue: No ]
    Overall survival (OS) was defined as the time from start of treatment to the date of death due to any cause. If a patient is not known to have died, survival was censored at the last date of contact. OS was to be reported at extension and after 3-year follow-up. The Kaplan-Meier median was used to analyze the OS.

Enrollment: 71
Study Start Date: February 2011
Study Completion Date: March 2014
Primary Completion Date: March 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: All Patients Drug: BKM120
Other Name: Buparlisib


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2
  • histologically confirmed diagnosis of advanced endometrial carcinoma with available tissue specimen for identification of PI3K pathway activation (archival tissue or a fixed fresh biopsy)
  • one prior line of antineoplastic treatment with a cytotoxic agent
  • objective progression of disease after prior treatment and at least one measurable lesion as per RECIST criteria
  • adequate bone marrow and organ function

Exclusion Criteria:

  • previous treatment with PI3K and/or mTOR inhibitors
  • symptomatic CNS metastases
  • concurrent malignancy or malignancy within 3 years of study enrollment
  • Active mood disorder as judged by investigator or medically documented history of mood disorder (e.g. major depressive episode, bipolar disorder, obsessive-compulsive disorder, schizophrenia, etc.), ≥ CTCAE grade 3 anxiety
  • pelvic and/or para-aortic radiotherapy ≤ 28 days prior to enrollment in the study
  • poorly controlled diabetes mellitus (HbA1c > 8 %)
  • history of cardiac dysfunction or active cardiac disease as specified in the protocol
  • impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BKM120

Other protocol-defined inclusion/exclusion criteria may apply

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01289041

  Show 42 Study Locations
Sponsors and Collaborators
Novartis Pharmaceuticals
Study Director: Novartis Pharmaceuticals Novartis Pharmaceuticals
  More Information

Responsible Party: Novartis ( Novartis Pharmaceuticals )
ClinicalTrials.gov Identifier: NCT01289041     History of Changes
Other Study ID Numbers: CBKM120C2201  2010-022015-19 
Study First Received: January 26, 2011
Results First Received: March 30, 2015
Last Updated: March 30, 2015
Health Authority: United States: Food and Drug Administration
Australia: Department of Health and Ageing Therapeutic Goods Administration
Belgium: Federal Agency for Medicinal Products and Health Products
Brazil: National Health Surveillance Agency
Canada: Health Canada
China: Food and Drug Administration
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Germany: Federal Institute for Drugs and Medical Devices
Italy: National Institute of Health
Japan: Pharmaceuticals and Medical Devices Agency
Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products
Russia: Ministry of Health of the Russian Federation
Singapore: Health Sciences Authority
Spain: Spanish Agency of Medicines
Turkey: Ministry of Health

Keywords provided by Novartis:
Advanced endometrial cancer
PI3K pathway
second-line treatment

ClinicalTrials.gov processed this record on April 27, 2016